Abeona Q3: ZEVASKYN Revenue $13.5M, Net Loss Narrows to $4.8M, $134.9M Cash
ABEO is trading near its 52-week low of $2.3 (9.6% above the low) on elevated volume (8.7× avg).
Summary
Abeona reported Q3 ZEVASKYN revenue of $13.5 million and a $4.8 million net loss, with $134.9 million in cash resources. A July manufacturing batch failed a release test, and a $30 million private placement is set to close November 10.
Key Events · Earnings and Guidance · ABEO
-
ZEVASKYN Revenue Reaches $13.5M in Q3
Product revenue rose to $13.5 million in Q3 2026 from $11.4 million in Q2, with nine-month revenue of $33.6 million against $12.6 million of cost of sales.
-
Net Loss Narrows to $4.8M
Q3 net loss was $4.8 million versus $5.2 million a year ago, aided by a $6.5 million non-cash gain on warrant remeasurement; nine-month net loss was $42.1 million.
-
Cash Resources of $134.9M
$66.3 million cash plus $68.7 million short-term investments at September 30, 2026; management says this funds operations for at least 12 months, against $45.6 million of nine-month operating cash burn.
-
Manufacturing Batch Failed Release Test
A July 2026 ZEVASKYN batch was out of specification on a cellular identity test; the FDA permitted single-patient IND release but not commercial release, and the company is seeking a specification revision.
Analysis · ABEO · Life Sciences
The ZEVASKYN launch is now producing real revenue: $13.5 million in Q3 versus $11.4 million in Q2. Quarterly net loss narrowed to $4.8 million, helped by a $6.5 million non-cash gain on warrant remeasurement. But the balance sheet is the story. At September 30, cash and short-term investments totaled $134.9 million, enough to fund operations for at least the next 12 months, and a $30 million private placement expected to close November 10 adds to that cushion. Against it, spending is heavy — $45.6 million of operating cash burn over nine months. The company also disclosed that a July 2026 ZEVASKYN batch failed a cellular identity release test and was only cleared by the FDA for single-patient use, not commercial sale. That manufacturing constraint, plus the $20 million stock acquisition of ABO-801, will determine whether revenue keeps compounding.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABEO was trading at $2.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $145.2M. The 52-week trading range was $2.30 to $7.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.